Dr. Paibel Aguayo-Hiraldo, MD
Claim this profileChildren's Hospital of Los Angeles
Studies Syndrome
Studies Anemia
6 reported clinical trials
16 drugs studied
Area of expertise
1Syndrome
SAMD9 positive
SAMD9L positive
GATA2 positive
2Anemia
SAMD9 positive
SAMD9L positive
GATA2 positive
Affiliated Hospitals
Clinical Trials Paibel Aguayo-Hiraldo, MD is currently running
IST + BMT
for Aplastic Anemia
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a secondary treatment in patients who did not get better with IST, had their disease come back, or a new worse disease replaced it (like leukemia). This trial will compare time from randomization to failure of treatment or death from any cause of IST versus URD BMT when used as initial therapy to treat SAA. The trial will also assess whether health-related quality of life and early markers of fertility differ between those randomized to URD BMT or IST, as well as assess the presence of marrow failure-related genes and presence of gene mutations associated with MDS or leukemia and the change in gene signatures after treatment in both study arms. This study treatment does not include any investigational drugs. The medicines and procedures in this study are standard for treatment of SAA.
Recruiting2 awards Phase 3
Steroid Tapering
for Pediatric Graft-versus-Host Disease
The standard treatment for acute graft-vs-host disease (GVHD) is to suppress the activity of the donor immune cells using steroid medications such as prednisone. Although most GVHD, especially in children, responds well to treatment, sometimes (around 1/3 of the time) there is either no response to steroids or the response does not last. In those cases, the GVHD can become dangerous and even life-threatening. Unfortunately, doctors cannot predict who will have a good response to treatment based on symptom severity or initial response to steroids. As a result, nearly all children who develop GVHD are treated with long courses of high dose steroids even though that means many patients receive more treatment than they probably need. Steroid treatment can cause short-term complications like infections, high blood sugar, high blood pressure, muscle weakness, depression, anxiety, and problems sleeping and long-term complications like bone damage, cataracts in the eyes, and decreased growth. The risk of these complications increases with higher doses of steroids and longer treatment. It is important to find ways to decrease the steroid treatment in patients who do not need long courses. The doctors conducting this research have developed a blood test (GVHD biomarkers) that predicts whether a patient will respond well to steroids. The study team found that children who have low GVHD biomarkers at the start of treatment and for the first two weeks of treatment have a very high response rate to steroids. In this study, the study team will monitor GVHD symptoms and biomarkers during treatment and taper steroids quickly in patients who have GVHD that is expected to respond very well to treatment. The study team will assess how many patients respond well to lower steroid dosing and what steroid complications develop. The study team will also use surveys to obtain the patient's own assessment of their quality of life (down to age 5 years).
Recruiting1 award Phase 2
More about Paibel Aguayo-Hiraldo, MD
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Paibel Aguayo-Hiraldo, MD has experience with
- Fludarabine
- Prednisone
- N/A
- Methotrexate
- Rabbit Anti-Thymocyte Globulin (ATG)
- Horse Anti-Thymocyte Globulin (ATG)
Breakdown of trials Paibel Aguayo-Hiraldo, MD has run
Syndrome
Graft-versus-Host Disease
Bone Marrow Transplant
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Paibel Aguayo-Hiraldo, MD specialize in?
Paibel Aguayo-Hiraldo, MD focuses on Syndrome and Anemia. In particular, much of their work with Syndrome has involved SAMD9 positive patients, or patients who are SAMD9L positive.
Is Paibel Aguayo-Hiraldo, MD currently recruiting for clinical trials?
Yes, Paibel Aguayo-Hiraldo, MD is currently recruiting for 3 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Paibel Aguayo-Hiraldo, MD has studied deeply?
Yes, Paibel Aguayo-Hiraldo, MD has studied treatments such as Fludarabine, Prednisone, N/A.
What is the best way to schedule an appointment with Paibel Aguayo-Hiraldo, MD?
Apply for one of the trials that Paibel Aguayo-Hiraldo, MD is conducting.
What is the office address of Paibel Aguayo-Hiraldo, MD?
The office of Paibel Aguayo-Hiraldo, MD is located at: Children's Hospital of Los Angeles, Los Angeles, California 90027 United States. This is the address for their practice at the Children's Hospital of Los Angeles.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.